Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
General Radiation Oncology
Is there an increased risk of spinal cord myelopathy in patients who have heterozygous ATM mutations?
Can bone mets in the vertebral body be treated with radiation in patients with ATM mutations?
Related Questions
Has there been an observed interaction between ACE inhibitors and development of angioedema in a block demarcated superficial radiation therapy treatment volume (ex. lip)?
What is your approach to management of radiation-induced bullous pemphigoid?
When do you prefer to use bolus for treating superficial tumors adjacent to or involving the skin surface, especially for complex surface anatomy in the pelvis, head/neck, and extremity regions?
What dose and fractionation would you use for a non-operable solitary fibrous tumor in the lumbar vertebra with definitive intent?
When do you offer adjuvant radiation therapy for a glomus tumor of uncertain malignant potential of the extremity resected with negative margins?
Are there any precautions you would take when radiating the pelvis in an obese patient with recent extensive ventral hernia repair to minimize dehiscence risk?
How do you manage a patient's pain from the skin tattoos placed at CT simulation?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
What is your preferred fractionation scheme for spine SBRT for radioresistant histologies?
Can patients receive adjuvant radiation therapy after keloid excision without primary closure, or would radiation impede healing by secondary intention?